Johns Hopkins Diabetes Guide
Naltrexone/Buproprion
INDICATIONS
FDA
FDA
- Naltrexone/bupropion was approved as an adjunct to diet and exercise in adults with BMI ≥30 kg/m2 or ≥27 kg/m2 with one or more weight-related comorbidities to achieve weight loss.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: August 22, 2017
Citation
Lee, Clare, and Brian Pinto. "Naltrexone/Buproprion." Johns Hopkins Diabetes Guide, 2017. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547197/6/Naltrexone_Buproprion.
Lee C, Pinto B. Naltrexone/Buproprion. Johns Hopkins Diabetes Guide. 2017. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547197/6/Naltrexone_Buproprion. Accessed September 23, 2023.
Lee, C., & Pinto, B. (2017). Naltrexone/Buproprion. In Johns Hopkins Diabetes Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547197/6/Naltrexone_Buproprion
Lee C, Pinto B. Naltrexone/Buproprion [Internet]. In: Johns Hopkins Diabetes Guide. ; 2017. [cited 2023 September 23]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547197/6/Naltrexone_Buproprion.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Naltrexone/Buproprion
ID - 547197
A1 - Lee,Clare,M.D., MHS
AU - Pinto,Brian,Pharm.D.
Y1 - 2017/08/22/
BT - Johns Hopkins Diabetes Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547197/6/Naltrexone_Buproprion
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
